Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» CPCF's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CPCF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:IRSB, OTCPK:PEYE, BOM:531380, BOM:533212, OTCPK:ECIA, OSTO:DOXA BTA » details

CPC of America, Inc. was formed under the laws of the State of Nevada on April 11, 1996. The Company is engaged in the business of developing and acquiring cardiology therapeutic and disposable devices and products as well as the manufacture and distribution of these devices and products. The Company is currently engaged in the development of the MedClose internal puncture closing delivery system device. MedClose utilizes any approved biological or synthetic sealants to close puncture wounds following surgical procedures utilizing arterial puncture access. To date, it has completed the development of an external counterpulsation device for the treatment of coronary artery disease known as the CPCA 2000. In March 2003, it received FDA clearance to market the CPCA 2000 counterpulsation unit as a Class III medical device. In addition, through its wholly-owned subsidiary, Med Enclosure, LLC, the Company is engaged in the business of developing a patented internal puncture closing device known as 'MedClose.' The MedClose is a vascular closure system medical device that is designed to seal arterial puncture sites in patients who have undergone diagnostic or interventional surgical procedures utilizing access via an arterial puncture site. The MedClose consists of a catheter system that is its proprietary product and utilizes any approved biologic or synthetic sealants. Subject to regulatory approval of the MedClose device, the Company to market the MedClose, mainly to hospitals and its procedure performing physicians through country, region and international distribution agreements. The Company has several competitors that manufacture and market puncture closure devices, including St. Jude Medical, Johnson & Johnson, Abbot Laboratories, Vascular Solutions and Access Controls, and there are several other companies that market competing products that are in the nature of wound devices. At present, the Company has submitted domestic and international applications to patent the CPCA 2000 and its counterpulsation technology and have been granted patents in Ireland and the United Kingdom and have received a trademark on the name 'CPCA 2000' and its logo in the United States. Clinical testing, manufacturing and distribution of the MedClose are subject to regulation by numerous governmental authorities, mainly the Food and Drug Administration (FDA) and corresponding state and foreign regulatory agencies.



Valuation & Return


More Statistics

EPS (TTM) $ -0.17
Short Percentage of Float0.00%
52-Week Range $0.00 - 0.10
Shares Outstanding (Mil)10.15
» More Articles for CPCF


Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)